ClinicalTrials.gg
CompletedNCT04943380DRIVEUpdated Apr 24, 2026

Efficacy and Utility of Cxbladder Tests in Hematuria Patients

An observational study in Hematuria and Urothelial Carcinoma, sponsored by Pacific Edge Limited. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Pacific Edge Limited · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
682
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Hematuria with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Hematuria · United States.

Started
2019
with 2 others
Observational
7 of 20
1 open now
Registered
12th of 20
by date
Lead sponsor
2 of 20
Pacific Edge Limited

Among the 20 studies in Hematuria with a site in United States, this one is one of 3 that started in 2019, is one of 7 observational ones, and was the 12th registered.

Hematuria

67 studies on the registry are indexed under Hematuria; 16 are open to participants now.

Browse Hematuria studies →

Open to participants now

5 of the 20 studies in Hematuria with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Hematuria studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hematuria with a site in United States, or all of them as a file.
02

Study summary

Prospective observational study to validate the performance characteristics and clinical utility of Cxbladder tests in a Veterans Affairs cohort.

Read the detailed description

Non-invasive, voided urine sample used for both Cxbladder molecular tests, voided urine sample may be used for standard of care testing. Retrospective analysis of data after study completion ensures a de-phasing of study sample analysis from clinical decision making; patient treatment and management.

The study aims to sequentially recruit up to 1000 patients presenting for assessment of hematuria (microscopic or macroscopic) by cystoscopy across multiple Veterans Affairs sites

03

Conditions studied

  • Hematuria
  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will be conducted with all hematuria patients who present to an outpatient clinic to undergo clinical assessment including cystoscopy and who fulfil study requirements. Consented eligible patients will attend their scheduled clinic visit and undergo all standard tests as clinically indicated.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria patients referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.
  • Able to provide a voided urine sample of the required minimum volume
  • Able to give written consent
  • Able and willing to comply with study requirements
  • Aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Prior history of bladder , prostate or renal cell carcinoma
  • Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection
  • Previous alkylating based chemotherapy
  • Known Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
682 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • patients with hematuria undergoing investigation for UC

    Patients will be recruited from those presenting with hematuria and undergoing investigative cystoscopy for the determination of possible urothelial carcinoma. This includes patients referred via imaging or from other departments for assessment of hematuria. Microscopic hematuria is defined as ≥ 3 red blood cells per high-powered microscopy field for a properly collected urine sample.

    Diagnostic Test: Cxbladder

Interventions

  • Diagnostic testCxbladder

    The Cxbladder Detect+ test is a molecular diagnostic test. The test consists of six DNA biomarkers and five RNA biomarkers measured in a small volume of urine. is an enhanced version of the Cxbladder Detect test.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with bladder cancer who are correctly identified as having cancer (true positives) and no cancer (true negatives) by the Cxbladder test.

    The Cxbladder test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity and specificity of the Cxbladder test for detecting urothelial cancer in patients with hematuria

    Time frame: From enrolment to when a UC diagnosis is made or patient is considered UC negative (maximum period 6-months)

  2. Probability that patients identified as having cancer and no cancer by the Cxbladder test truly have cancer (positive predictive value; PPV), and truly have no cancer (negative predictive value; NPV) respectively.

    The Cxbladder test results will be compared to that of cystoscopy, which is the gold standard method for diagnosing urothelial cancer; the true positive and true negative rates will be measured, along with the false positive and false negative rates of the test. The results will be reported as sensitivity and specificity of the Cxbladder test for detecting urothelial cancer in patients with recurrent disease.

    Time frame: From enrolment to when a UC diagnosis is made or patient is considered UC negative (maximum period 6-months).

Secondary outcomes

  1. To identify whether patients received a UC diagnosis 6- and 24-months post urine sample collection

    To identify by records review within six months and up to 24-months after the initial urine sample collection whether the patient received a diagnosis of UC of the bladder and/or upper tract.

    Time frame: The outcome measure will be assessed by 6- and up to 24-months after trial completion.

  2. Validation of performance characteristics of Cxbladder tests through sub-group analyses

    To validate the performance characteristics (sensitivity, specificity, negative predictive value, positive predictive value) and true negative rate of Cxbladder tests through sub-group analysis (gross hematuria; microhematuria; inflammation), in a VA cohort, for patients with a recent history of hematuria who are undergoing investigative cystoscopy.

    Time frame: From enrolment to when a UC diagnosis is made or patient is considered UC negative (maximum period 6-months).

  3. Comparison of the Cxbladder test's sensitivity, specificity, PPV and NPV with that of Cytology.

    Performance characteristics (sensitivity, specificity, PPV and NPV) of the Cxbladder test for detecting recurring urothelial cancer will be compared to urine cytology, in addition to the gold standard test (cystoscopy). All comparator tests will be carried out on the same voided urine sample used for Cxbladder tests.

    Time frame: From enrolment to when a UC diagnosis is made or patient is considered UC negative (maximum period 6-months).

  4. To compare the theoretical clinical outcome of patients tested using Cxbladder signatures before investigative cystoscopy with evaluation by cystoscopy alone to establish the true proportion requiring cystoscopy.

    To compare the theoretical clinical outcome of patients tested using Cxbladder signatures before investigative cystoscopy with evaluation by (positive, negative or suspicious) cystoscopy alone to establish the true proportion requiring cystoscopy, thereby determining the potential of Cxbladder to reduce or adjudicate the cystoscopy burden of hematuria patients and/or sub cohorts under clinical evaluation in a hospital urology clinic setting.

    Time frame: From enrolment to when a UC diagnosis is made or patient is considered UC negative (maximum period 6-months).

  5. Performance characteristics of Cxbladder Triage and Cxbladder Detect compared with results generated at other clinical sites

    To evaluate the performance characteristics of Cxbladder Triage and Cxbladder Detect compared with results generated at other clinical sites, and to the results of the pulished clinical studies by O'Sullivan et al in 2012 and Kavalieris et al in 2015

    Time frame: The outcome measure will be assessed from enrolment to when a UC diagnosis is made or patient is considered UC negative for this trial (maximum period 24-months) and completed following completion of other similar trials.

07

Study locations

10 sites
  • Veterans Medical Research Foundation
    San Diego, California 92161, United States
  • Bay Pines Veterans Affairs
    Bay Pines, Florida 33744-8200, United States
  • South Florida Veterans Affairs
    Miami, Florida 33125, United States
  • James A Haley Veterans' Hospital
    Tampa, Florida 33612-4745, United States
  • Minneapolis VA Health Care System
    Minneapolis, Minnesota 55417, United States
  • NWIHCS-Omaha VA Medical Center
    Omaha, Nebraska 68105, United States
  • James J. Peters VAMC
    New York, New York 10468-3904, United States
  • Oklahoma City VA Hospital
    Oklahoma City, Oklahoma 73104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29401, United States
  • White River Junction VAMC
    White River Junction, Vermont 05009, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jan 2024, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Jun 29, 2021
StartActual
Nov 8, 2019
Primary completionActual
Jan 18, 2024
CompletionActual
Jan 18, 2024
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04943380
Lead sponsor
Pacific Edge Limited
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
Nov 8, 2019
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024
Last update
Apr 24, 2026

Study contacts

Tony Lough, PhD
study chair · Pacific Edge Pty Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion